Abstract |
In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.
|
Authors | Evangéline Pillebout, Fabiane Rocha, Laurence Fardet, Michel Rybojad, Jérôme Verine, Denis Glotz |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 26
Issue 6
Pg. 2044-6
(Jun 2011)
ISSN: 1460-2385 [Electronic] England |
PMID | 21436378
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Immunologic Factors
- Rituximab
|
Topics |
- Adult
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Humans
- IgA Vasculitis
(drug therapy)
- Immunologic Factors
(therapeutic use)
- Immunomodulation
- Male
- Rituximab
- Treatment Outcome
- Young Adult
|